Arman Qamar MD MPH

A biomarker risk score approach identifies patients deriving highest absolute benefit from intensive LDL lowering with ezetimibe. @TIMIStudyGroup @rgiugliano @califf001 @cpcannon #EugeneBraunwald #DavidMorrow #IMPROVEIT @precisionfda @HarvardChanSPH onlinejacc.org/content/74/8/1…

Read our latest contemporary review on polygenic risk in venous thromboembolism. Polygenic risk score improves risk prediction, guides anticoagulant use, and helps tailor prevention. @AqamarMD @MananPareekMD @KMAlexanderMD Link: rpthjournal.org/article/S2475-…

We are Routinely Evaluating VTE PRS in the Clinic in Many of Our Patients With Unprovoked VTE - @AqamarMD @RPTHjournal @AJTafur hemostasistoday.com/insight/arman-… #Health #Hematology #Hemostasis #MedED #MedX #HemostasisToday #VTERiskPrediction #Medicine #PolygenicRiskScore #PRS #RPTHJournal #VTEPRS

@Abdul_Qadeer_MD @pruthap287 @drshehryar007 Great work !

Wrapped up an amazing week at #SCAI2025 in Washington, DC! Huge thanks to the incredible mentor, Dr. Arman Qamar for the inspiration and guidance and my research team at MCA and HVRA.

@HarshGMD @AvinainderSingh @ShahzebKhanMD @EndeavorHlth

Exciting opportunity! We’re looking for a Cardiovascular Outcomes Research Fellow to join our team at Endeavor Health. If you’re passionate about advancing CV research & making a real impact, apply now! DM for more details. #Hiring @mj_ricciardi @HeartOTXHeartMD @SripalBangalore

Thanks to many who attended our CVI Personalized Medicine Symposium: genomicmd.com/endeavor-cardi… @EndeavorHlth @amitvkhera @GenomicMD @EndeavorHlth

Great discussing ORBITA-STAR: ORBITA-STAR Highlights Variability in Symptom Changes Post-PCI tctmd.com/news/orbita-st… @EndeavorHlth @HeartOTXHeartMD @mj_ricciardi

Our new work in #Atherosclerosis @ATHjournal studying the association of PAD, CKD and recurrent admissions for ADHF. Special thank you to @CaugheyPhD for her great mentorship! sciencedirect.com/science/articl…

Among patients hospitalized w/ ADHF, those w/ concurrent PAD have more prevalent 🫀 comorbidities and higher likelihood of 1-y ADHF readmission, irrespective of CKD status 🔗atherosclerosis-journal.com/article/S0021-… @zainchunawala @DLBHATTMD @AqamarMD @mvaduganathan @robmentz @JLGrodin @CaugheyPhD

@agtruesdell @ShashankSinhaMD @SCAI @BurkhoffMd @dranulala @JasonKatzMD @OrenFriedman @FMaeWestMD @IM_Crit_ @ERC_resus @BenjaminAbella @glennfishman @CardsNYC @SripalBangalore @carlosalviar @bhwords @GBarnesMD @DrDrewKleinPHI @mdonnino @VTEIreland 🔥The #FlowTriever Arm primary endpoint was compared to a performance goal of 32%, based on a published meta-analysis The magnitude of the benefit was so large in #FLAME that investigators stopped the study early to share these outcomes at #ACC23 earlier this year

@jpirruccello @TCTMD_Yael @HeartOTXHeartMD @mj_ricciardi @NorthShoreWeb Agree James, long term dapt with ticag 60 beyond 1 year is reasonable approach.

Great summary on antiplatelet therapy for 2nd-prevention @TCTMD_Yael @HeartOTXHeartMD @mj_ricciardi @NorthShoreWeb

@mj_ricciardi @TCTMD_Yael @HeartOTXHeartMD @NorthShoreWeb @TCTMD Thanks Mark!

@AqamarMD @TCTMD_Yael @HeartOTXHeartMD @NorthShoreWeb @NorthShoreWeb we’ve become accustomed to @AqamarMD brilliant insights for all things antiplt and anticoag. Nice to see these expert’s views on @TCTMD 💪

Great #CardioTwitter research showcase @NorthShoreWeb IMED #GrandRounds this morning w @mj_ricciardi , @AqamarMD , and David Davidson. Great team we have here!

@docmohitgupta @durgeshjhaTOI @smittal_ips @DLBHATTMD @mmamas1973 @ICMRDELHI Great work @docmohitgupta

Landmark Analysis: Covid 19 Vaccination in India ( covishield and covaxin) doesn’t lead to more heart attack & has protective effect on patients of heart attack. Plos-One 2023. More than 1500 patients. @durgeshjhaTOI @smittal_ips @DLBHATTMD @AqamarMD”@mmamas1973 @ICMRDELHI

Ten current papers for the curious general cardiologist, including ticagrelor monotherapy post PCI, MRA use in cardiac amyloid, asystole post shock from wearable defibs & ⬇️in mortality using telemonitoring in HF Sources: @ESC_Journals, @JACCJournals, @JAMACardio 1/n

@BharatRawlley @UpstateNews @InnovateUpstate @UpstateIM_Res @UpstateCardiol1 @UCMSofficial @krtkgpt @HFHCardioFellow @ACordova92 @uvmcards @KannuBansalMD @BIDMCNeuroRes @harvardmed @AnkurKalraMD @UtkarshDayal @i_salooja @DhawaniJ @hvanspall @ErinMichos @ShahzebKhanMD @SameerAroraMD Great work! Congratulations

@UpstateNews @InnovateUpstate @UpstateIM_Res @UpstateCardiol1 @UCMSofficial @krtkgpt @HFHCardioFellow @ACordova92 @uvmcards @KannuBansalMD @BIDMCNeuroRes @harvardmed @AnkurKalraMD @UtkarshDayal @i_salooja @DhawaniJ @hvanspall @ErinMichos @ShahzebKhanMD @AqamarMD @SameerAroraMD

Excited to share our manuscript published in the @AmJCardio ; Trends in Data Monitoring Committees, Randomization, and Blinding in Cardiovascular Disease Studies on ClinicalTrials.gov from 2012 to 2021 authors.elsevier.com/c/1ha6ggQkyqks